An organometallic inhibitor for glycogen synthase kinase 3

Journal of the American Chemical Society

Volumn 126, Issue 42, 2004, Pages 13594-13595

  Bregman, Howard ^a   Williams, Douglas S ^a   Atilla, G Ekin ^a   Carroll, Patrick J ^a   Meggers, Eric ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CARBAZOLE DERIVATIVE; GLYCOGEN SYNTHASE KINASE 3; INDOLE DERIVATIVE; INDOLO[2,3 A]CARBAZOLE AGLYCON; ORGANOMETALLIC COMPOUND; RUTHENIUM; STAUROSPORINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CORRELATION ANALYSIS; COVALENT BOND; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; HYDROGEN BOND; IC 50; STRUCTURE ANALYSIS;

CARBAZOLES; CRYSTALLOGRAPHY, X-RAY; GLYCOGEN SYNTHASE KINASE 3; INDOLES; KINETICS; MODELS, MOLECULAR; ORGANOMETALLIC COMPOUNDS; PROTEIN KINASE INHIBITORS; RUTHENIUM;

EID: 6444236961     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja046049c     Document Type: Article

References (18)

1. Metal-based drugs: (a) Orvig, C.; Abrams, M. J. (Eds.) Chem. Rev. 1999, 99, 2201-2842. (b) Guo, Z.; Sadler, P. J. Angew. Chem., Int. Ed. 1999, 38, 1512-1531. (c) Farrell, N. (Ed.) Coord. Chem. Rev. 2002, 232, 1-230.
2. Metal-based drugs: (a) Orvig, C.; Abrams, M. J. (Eds.) Chem. Rev. 1999, 99, 2201-2842. (b) Guo, Z.; Sadler, P. J. Angew. Chem., Int. Ed. 1999, 38, 1512-1531. (c) Farrell, N. (Ed.) Coord. Chem. Rev. 2002, 232, 1-230.
3. Metal-based drugs: (a) Orvig, C.; Abrams, M. J. (Eds.) Chem. Rev. 1999, 99, 2201-2842. (b) Guo, Z.; Sadler, P. J. Angew. Chem., Int. Ed. 1999, 38, 1512-1531. (c) Farrell, N. (Ed.) Coord. Chem. Rev. 2002, 232, 1-230.
4. Metal complexes as enzyme inhibitors: Louie, A. Y.; Meade, T. J. Chem. Rev. 1999, 99, 2711-2734.
5. For pioneering work, see: (a) Dwyer, F. P.; Gyarfas, E. C.; Rogers, W. P.; Koch, J. H. Nature 1952, 170, 190-191. (b) Dwyer, F. P.; Gyarfas, E. C.; Wright, R. D.; Shulman, A. Nature 1957, 179, 425-426.
6. For pioneering work, see: (a) Dwyer, F. P.; Gyarfas, E. C.; Rogers, W. P.; Koch, J. H. Nature 1952, 170, 190-191. (b) Dwyer, F. P.; Gyarfas, E. C.; Wright, R. D.; Shulman, A. Nature 1957, 179, 425-426.
7. Taube, H. Chem. Rev. 1952, 50, 69-126.
8. Zhang, L.; Carroll, P. J.; Meggers, E. Org. Lett. 2004, 6, 521-523.
9. Taylor, S. S.; Radzio-Andzelm, E. Curr. Opin. Chem. Biol. 1997, 1, 219-226.
10. (a) García-Echevería, C.; Traxler, P.; Evans, D. B. Med. Res. Rev. 2000, 20, 28-57.
11. (b) Bridges, A. J. Chem. Rev. 2001, 101, 2541-2571.
12. (a) Toledo, L. M.; Lydon, N. B. Structure 1997, 5, 1551-1556.
13. (b) Lawrie, A. M.; Noble, M. E. M.; Tunnah, P.; Brown, N. R.; Johnson, L. N.; Endicott, J. A. Nat. Struct. Biol. 1997, 4, 796-801.
14. A related cycloruthenation of 2-pyridylindoles and 2-pyridylpyrroles has been reported, but no structures were provided: (a) Thummel, R. P.; Hedge, V. J. Org. Chem. 1989, 54, 1720-1725. (b) Wu, F.; Chamchoumis, C. M.; Thummel, R. P. Inorg. Chem. 2000, 39, 584-590.
15. A related cycloruthenation of 2-pyridylindoles and 2-pyridylpyrroles has been reported, but no structures were provided: (a) Thummel, R. P.; Hedge, V. J. Org. Chem. 1989, 54, 1720-1725. (b) Wu, F.; Chamchoumis, C. M.; Thummel, R. P. Inorg. Chem. 2000, 39, 584-590.
16. Brunner, H. Angew. Chem., Int. Ed. 1999, 38, 1194-1208.
17. Bertrand. J. A.; Thieffine, S.; Vulpetti, A.; Cristiani, C.; Valsasina, B.; Knapp, S.; Kalisz, H. M.; Flocco, M. J. Mol. Biol. 2003, 333, 393-407.
18. Cohen, P.; Goedert, M. Nat. Rev. Drug Discov. 2004, 3, 479-487.